Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?
- PMID: 15588853
- DOI: 10.1016/j.cancergencyto.2004.04.004
Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?
Abstract
This study was designed to determine if cytological detection of 5-methylcytosine (5MC) was feasible on prostate tumor sections and to determine if levels of 5MC differed in malignant compared to normal prostate tissue. We further sought to see if 5MC levels correlated with any clinical outcome data. Thirty prostate tumor sections were obtained from patients who underwent radical prostatectomies from 1988 to 1995; these represented a mix of low to high grade tumors. Clinical data were maintained for each of these patients with a minimum of 7 years of follow up. Sections were stained with a commercially available antibody to 5MC and immunocytochemistry levels were subsequently quantified using a computer-assisted true-color imaging system. Tumor and benign regions of the same archived sections were compared, in addition to a series of 12 normal prostate samples. Prostate cancer cells exhibited a pronounced global decrease in methylation compared with benign and normal tissue. This was observed in 29 of 30 patients (96.7%) studied and densitometric scanning of methylation staining indicated that this value was quantifiable. Overall, higher methylation values were detected in men who had positive surgical margins and recurrent disease. These data suggest that loss of methylation is a feature of prostate cancer, and partial gain of methylation (presumably at promoters of specific genes) is associated with clinical outcome and is measurable using whole-cell assays.
Similar articles
-
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.Clin Cancer Res. 2007 Oct 15;13(20):6122-9. doi: 10.1158/1078-0432.CCR-07-1042. Clin Cancer Res. 2007. PMID: 17947477
-
A quantitative promoter methylation profile of prostate cancer.Clin Cancer Res. 2004 Dec 15;10(24):8472-8. doi: 10.1158/1078-0432.CCR-04-0894. Clin Cancer Res. 2004. PMID: 15623627
-
In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer.Exp Mol Pathol. 2007 Jun;82(3):292-7. doi: 10.1016/j.yexmp.2006.08.002. Epub 2006 Oct 5. Exp Mol Pathol. 2007. PMID: 17026997
-
Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.Anal Biochem. 2009 Sep 15;392(2):117-25. doi: 10.1016/j.ab.2009.06.001. Epub 2009 Jun 6. Anal Biochem. 2009. PMID: 19505431
-
The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.J Urol. 2007 Mar;177(3):822-31. doi: 10.1016/j.juro.2006.10.063. J Urol. 2007. PMID: 17296351 Review.
Cited by
-
Environmental chemical exposures and human epigenetics.Int J Epidemiol. 2012 Feb;41(1):79-105. doi: 10.1093/ije/dyr154. Epub 2011 Dec 13. Int J Epidemiol. 2012. PMID: 22253299 Free PMC article.
-
Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia.Hum Genomics. 2016 Jul 25;10 Suppl 2(Suppl 2):18. doi: 10.1186/s40246-016-0071-5. Hum Genomics. 2016. PMID: 27461342 Free PMC article.
-
PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer.Transl Cancer Res. 2021 May;10(5):2153-2168. doi: 10.21037/tcr-20-3295. Transl Cancer Res. 2021. PMID: 35116535 Free PMC article.
-
Epidrugs: targeting epigenetic marks in cancer treatment.Epigenetics. 2019 Dec;14(12):1164-1176. doi: 10.1080/15592294.2019.1640546. Epub 2019 Jul 13. Epigenetics. 2019. PMID: 31282279 Free PMC article. Review.
-
Rise in serum folate after androgen deprivation associated with worse prostate cancer-specific survival.Urol Oncol. 2020 Aug;38(8):682.e21-682.e27. doi: 10.1016/j.urolonc.2020.04.003. Epub 2020 May 20. Urol Oncol. 2020. PMID: 32444177 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical